This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): vanutide cridificar, PF-5326806, PF-05236806
Description: ACC-001 is a follow on vaccine to AN-1792, whose development was halted due to a side effect of central nervous system inflammation. ACC-001 is a truncated version that was designed to be less immunogenic.
The purpose of ACC-001 is to induce a specific antibody response in order to clear amyloid beta peptide, a putative causative factor in Alzheimer's disease.
Elan research indicates that antibodies specific for amyloid beta can cross the blood-brain barrier and act directly in the central nervous system to induce plaque clearance.
Deal Structure: ACC-001 was originally developed by Elan.
Elan and Wyeth
Elan and Wyeth's Alzheimer's Immunotherapy Program (AIP) is a 50:50 collaboration to research, develop and commercialize an immunotherapeutic approach that may be used for the treatment of mild to moderate AD and possibly to prevent the onset of the disease. AIP programs include ACC-001.
Elan has a commercial license for the use of QS-21 in research and commercialization of products. Under the terms of the agreement, Antigenics is entitled to receive future milestone payments and product royalties in the event of the successful development of Elan's Alzheimer's disease vaccine that contains QS-21.
Pfizer and Wyeth
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion.
In October 2009, Pfizer completed its...See full deal structure in Biomedtracker
Partners: Pfizer Inc. Agenus Inc. Perrigo Company PLC
Pink Sheet Elan Restarts Phase II Alzheimer’s Trial
Additional information available to subscribers only: